Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Kidney Transplantation | Research article

Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study

Authors: Gregory J. Wilson, Yeoungjee Cho, Armando Teixiera-Pinto, Nicole Isbel, Scott Campbell, Carmel Hawley, David W. Johnson

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

Membranoproliferative glomerulonephritis (MPGN) is an uncommon cause of end stage kidney disease (ESKD) and the clinical outcomes of patients with MPGN who commence kidney replacement therapy have not been comprehensively studied.

Methods

All adult patients with ESKD due to glomerulonephritis commencing kidney replacement therapy in Australia and New Zealand from January 1, 1996 to December 31, 2016 were reviewed. Patients with ESKD due to MPGN were compared to patients with other forms of glomerulonephritis. Patient survival on dialysis and following kidney transplantation, kidney recovery on dialysis, time to transplantation, allograft survival, death-censored allograft survival and disease recurrence post-transplant were compared between the two groups using Kaplan Meier survival curves and Cox proportional hazards regression.

Results

Of 56,481 patients included, 456 (0.8%) had MPGN and 12,660 (22.4%) had another form of glomerulonephritis. Five-year patient survival on dialysis and following kidney transplantation were similar between patients with ESKD from MPGN and other forms of glomerulonephritis (Dialysis: 59% vs. 62% p = 0.61; Transplant: 93% vs. 93%, p = 0.49). Compared to patients with other forms of glomerulonephritis, patients with MPGN had significantly poorer 5-year allograft survival (70% vs. 81% respectively, p = 0.02) and death censored allograft survival (74% vs. 87%, respectively; p < 0.01). The risk of disease recurrence was significantly higher in patients with MPGN compared to patients with other glomerulonephritidites (18% vs. 5%; p < 0.01). In patients with MPGN who had allograft loss, patients with MPGN recurrence had a significantly shorter time to allograft loss compared to patients with MPGN who had allograft loss due to any other cause (median time to allograft loss 3.2 years vs. 4.4 years, p < 0.01).

Conclusions

Compared with other forms of glomerulonephritis, patients with MPGN experienced comparable rates of survival on dialysis and following kidney transplantation, but significantly higher rates of allograft loss due to disease recurrence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis. 2011;57(2):291–9.CrossRef Angelo JR, Bell CS, Braun MC. Allograft failure in kidney transplant recipients with membranoproliferative glomerulonephritis. Am J Kidney Dis. 2011;57(2):291–9.CrossRef
2.
go back to reference McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.CrossRef McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.CrossRef
3.
go back to reference Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int. 2010;77(8):721–8.CrossRef Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int. 2010;77(8):721–8.CrossRef
4.
go back to reference Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, et al. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2018;22(4):797–807.CrossRef Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, et al. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol. 2018;22(4):797–807.CrossRef
5.
go back to reference Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006;69(3):504–11.CrossRef Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int. 2006;69(3):504–11.CrossRef
6.
go back to reference Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–9.CrossRef Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–9.CrossRef
7.
go back to reference Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol. 2016;17(1):7.CrossRef Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. BMC Nephrol. 2016;17(1):7.CrossRef
8.
go back to reference Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol Berl Ger. 2010;25(8):1409–18.CrossRef Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol Berl Ger. 2010;25(8):1409–18.CrossRef
9.
go back to reference O’Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC. Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol. 2017;28(2):632–44.CrossRef O’Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC. Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol. 2017;28(2):632–44.CrossRef
10.
go back to reference Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, et al. Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry. Transplantation. 2016;100(9):1955.CrossRef Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, et al. Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry. Transplantation. 2016;100(9):1955.CrossRef
11.
go back to reference Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int. 2017;92(2):461–9.CrossRef Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, et al. Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes. Kidney Int. 2017;92(2):461–9.CrossRef
12.
go back to reference Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28.CrossRef Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28.CrossRef
13.
go back to reference Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.CrossRef Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.CrossRef
14.
go back to reference Therneau TM. A package for survival analysis in R [internet]; 2015. Therneau TM. A package for survival analysis in R [internet]; 2015.
15.
go back to reference Kassambara A, Kosinski M. survminer: drawing survival curves using “ggplot2”; 2018. Kassambara A, Kosinski M. survminer: drawing survival curves using “ggplot2”; 2018.
16.
go back to reference R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016.
17.
go back to reference Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014;25(5):1110–7.CrossRef Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr SH, Gandhi MJ, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014;25(5):1110–7.CrossRef
18.
go back to reference Martín B, Smith RJ. C3 Glomerulopathy. Seattle: GeneReviews; 1993. Martín B, Smith RJ. C3 Glomerulopathy. Seattle: GeneReviews; 1993.
19.
go back to reference Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(s2):61–80.CrossRef Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(s2):61–80.CrossRef
20.
go back to reference Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Melbourne: Gastroenterological Society of Australia; 2018. Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Melbourne: Gastroenterological Society of Australia; 2018.
21.
go back to reference Bowie EA, Collins JF, Doak PB, Gregory MC, North JDK, Richmond DE, et al. The New Zealand glomerulonephritis study: introductory report. Clin Nephrol. 1989;31:239–46. Bowie EA, Collins JF, Doak PB, Gregory MC, North JDK, Richmond DE, et al. The New Zealand glomerulonephritis study: introductory report. Clin Nephrol. 1989;31:239–46.
22.
go back to reference Stewart JH, McCredie MRE, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in indigenous Australians. Nephrol Dial Transplant. 2004;19(3):678–85.CrossRef Stewart JH, McCredie MRE, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in indigenous Australians. Nephrol Dial Transplant. 2004;19(3):678–85.CrossRef
23.
go back to reference Ellison-Loschmann L, Pearce N. Improving access to health care among New Zealand’s Maori population. Am J Public Health. 2006;96(4):612–7.CrossRef Ellison-Loschmann L, Pearce N. Improving access to health care among New Zealand’s Maori population. Am J Public Health. 2006;96(4):612–7.CrossRef
24.
go back to reference Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9(6):377–85.CrossRef Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9(6):377–85.CrossRef
Metadata
Title
Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study
Authors
Gregory J. Wilson
Yeoungjee Cho
Armando Teixiera-Pinto
Nicole Isbel
Scott Campbell
Carmel Hawley
David W. Johnson
Publication date
01-12-2019

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue